{"pmid":32354030,"title":"Functional Role of Dietary Intervention to Improve the Outcome of COVID-19: A Hypothesis of Work.","text":["Functional Role of Dietary Intervention to Improve the Outcome of COVID-19: A Hypothesis of Work.","BACKGROUND: On the 31 December 2019, the World Health Organization (WHO) was informed of a cluster of cases of pneumonia of unknown origin detected in Wuhan City, Hubei Province, China. The infection spread first in China and then in the rest of the world, and on the 11th of March, the WHO declared that COVID-19 was a pandemic. Taking into consideration the mortality rate of COVID-19, about 5-7%, and the percentage of positive patients admitted to intensive care units being 9-11%, it should be mandatory to consider and take all necessary measures to contain the COVID-19 infection. Moreover, given the recent evidence in different hospitals suggesting IL-6 and TNF-alpha inhibitor drugs as a possible therapy for COVID-19, we aimed to highlight that a dietary intervention could be useful to prevent the infection and/or to ameliorate the outcomes during therapy. Considering that the COVID-19 infection can generate a mild or highly acute respiratory syndrome with a consequent release of pro-inflammatory cytokines, including IL-6 and TNF-alpha, a dietary regimen modification in order to improve the levels of adiponectin could be very useful both to prevent the infection and to take care of patients, improving their outcomes.","Int J Mol Sci","Messina, Giovanni","Polito, Rita","Monda, Vincenzo","Cipolloni, Luigi","Di Nunno, Nunzio","Di Mizio, Giulio","Murabito, Paolo","Carotenuto, Marco","Messina, Antonietta","Pisanelli, Daniela","Valenzano, Anna","Cibelli, Giuseppe","Scarinci, Alessia","Monda, Marcellino","Sessa, Francesco","32354030"],"abstract":["BACKGROUND: On the 31 December 2019, the World Health Organization (WHO) was informed of a cluster of cases of pneumonia of unknown origin detected in Wuhan City, Hubei Province, China. The infection spread first in China and then in the rest of the world, and on the 11th of March, the WHO declared that COVID-19 was a pandemic. Taking into consideration the mortality rate of COVID-19, about 5-7%, and the percentage of positive patients admitted to intensive care units being 9-11%, it should be mandatory to consider and take all necessary measures to contain the COVID-19 infection. Moreover, given the recent evidence in different hospitals suggesting IL-6 and TNF-alpha inhibitor drugs as a possible therapy for COVID-19, we aimed to highlight that a dietary intervention could be useful to prevent the infection and/or to ameliorate the outcomes during therapy. Considering that the COVID-19 infection can generate a mild or highly acute respiratory syndrome with a consequent release of pro-inflammatory cytokines, including IL-6 and TNF-alpha, a dietary regimen modification in order to improve the levels of adiponectin could be very useful both to prevent the infection and to take care of patients, improving their outcomes."],"journal":"Int J Mol Sci","authors":["Messina, Giovanni","Polito, Rita","Monda, Vincenzo","Cipolloni, Luigi","Di Nunno, Nunzio","Di Mizio, Giulio","Murabito, Paolo","Carotenuto, Marco","Messina, Antonietta","Pisanelli, Daniela","Valenzano, Anna","Cibelli, Giuseppe","Scarinci, Alessia","Monda, Marcellino","Sessa, Francesco"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32354030","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.3390/ijms21093104","keywords":["covid-19","il-6","adiponectin","diet therapies","lung infections","omega-3 pufas"],"locations":["Wuhan","Hubei","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495210487808,"score":9.490897,"similar":[{"pmid":32317220,"pmcid":"PMC7164894","title":"The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19.","text":["The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19.","The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has posed the world at a pandemic risk. Coronavirus-19 disease (COVID-19) is an infectious disease caused by SARS-CoV-2, which causes pneumonia, requires intensive care unit hospitalization in about 10% of cases and can lead to a fatal outcome. Several efforts are currently made to find a treatment for COVID-19 patients. So far, several anti-viral and immunosuppressive or immunomodulating drugs have demonstrated some efficacy on COVID-19 both in vitro and in animal models as well as in cases series. In COVID-19 patients a pro-inflammatory status with high levels of interleukin (IL)-1B, IL-1 receptor (R)A and tumor necrosis factor (TNF)-alpha has been demonstrated. Moreover, high levels of IL-6 and TNF-alpha have been observed in patients requiring intensive-care-unit hospitalization. This provided rationale for the use of anti-rheumatic drugs as potential treatments for this severe viral infection. Other agents, such as hydroxychloroquine and chloroquine might have a direct anti-viral effect. The anti-viral aspect of immunosuppressants towards a variety of viruses has been known since long time and it is herein discussed in the view of searching for a potential treatment for SARS-CoV-2 infection.","J Autoimmun","Perricone, Carlo","Triggianese, Paola","Bartoloni, Elena","Cafaro, Giacomo","Bonifacio, Angelo F","Bursi, Roberto","Perricone, Roberto","Gerli, Roberto","32317220"],"abstract":["The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has posed the world at a pandemic risk. Coronavirus-19 disease (COVID-19) is an infectious disease caused by SARS-CoV-2, which causes pneumonia, requires intensive care unit hospitalization in about 10% of cases and can lead to a fatal outcome. Several efforts are currently made to find a treatment for COVID-19 patients. So far, several anti-viral and immunosuppressive or immunomodulating drugs have demonstrated some efficacy on COVID-19 both in vitro and in animal models as well as in cases series. In COVID-19 patients a pro-inflammatory status with high levels of interleukin (IL)-1B, IL-1 receptor (R)A and tumor necrosis factor (TNF)-alpha has been demonstrated. Moreover, high levels of IL-6 and TNF-alpha have been observed in patients requiring intensive-care-unit hospitalization. This provided rationale for the use of anti-rheumatic drugs as potential treatments for this severe viral infection. Other agents, such as hydroxychloroquine and chloroquine might have a direct anti-viral effect. The anti-viral aspect of immunosuppressants towards a variety of viruses has been known since long time and it is herein discussed in the view of searching for a potential treatment for SARS-CoV-2 infection."],"journal":"J Autoimmun","authors":["Perricone, Carlo","Triggianese, Paola","Bartoloni, Elena","Cafaro, Giacomo","Bonifacio, Angelo F","Bursi, Roberto","Perricone, Roberto","Gerli, Roberto"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317220","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jaut.2020.102468","keywords":["autoimmunity","biologics","covid-19","coronavirus","dmards","il-6","immunosuppressant. il-1","infection","rheumatic","sars-cov-2","tdmards"],"e_drugs":["Hydroxychloroquine","Chloroquine"],"topics":["Treatment"],"weight":1,"_version_":1666138493622943744,"score":224.37427},{"pmid":32452979,"title":"Pediatric Crohn's Disease and Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19 Treated with Infliximab.","text":["Pediatric Crohn's Disease and Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19 Treated with Infliximab.","Coronavirus disease 2019 (COVID-19) may lead to a severe inflammatory response referred to as a cytokine storm. We describe a case of severe COVID-19 infection in a recently diagnosed pediatric Crohn's disease patient successfully treated with Tumor Necrosis Factor-alpha (TNF-alpha) blockade. The patient presented with five days of fever, an erythematous maculopapular facial rash, and abdominal pain without respiratory symptoms. SARS-CoV-2 PCR was positive. Despite inpatient treatment for COVID-19 and a perianal abscess, the patient acutely decompensated, with worsening fever, tachycardia, fluid-refractory hypotension, elevation of liver enzymes, and transformation of the rash into purpura extending from the face to the trunk, upper and lower extremities, including the palmar and plantar surfaces of the hands and feet. Cytokine profile revealed rising levels of interleukin (IL)-6, IL-8, and TNF-alpha, higher than those described in either inflammatory bowel disease (IBD) or severe COVID-19 alone. The patient was treated with infliximab for TNF-alpha blockade to address both moderately to severely active Crohn's disease and multisystem inflammatory syndrome in children (MIS-C) temporally related to COVID-19. Within hours of infliximab treatment, fever, tachycardia and hypotension resolved. Cytokine profile improved with normalization of TNF-alpha, a decrease in IL-6, and IL-8 concentrations. This case supports a role for blockade of TNF-alpha in the treatment of COVID-19 inflammatory cascade. The role of anti-TNF agents in patients with MIS-C temporally related to COVID-19 requires further investigation.","J Pediatr Gastroenterol Nutr","Dolinger, Michael T","Person, Hannibal","Smith, Rachel","Jarchin, Lauren","Pittman, Nanci","Dubinsky, Marla C","Lai, Joanne","32452979"],"abstract":["Coronavirus disease 2019 (COVID-19) may lead to a severe inflammatory response referred to as a cytokine storm. We describe a case of severe COVID-19 infection in a recently diagnosed pediatric Crohn's disease patient successfully treated with Tumor Necrosis Factor-alpha (TNF-alpha) blockade. The patient presented with five days of fever, an erythematous maculopapular facial rash, and abdominal pain without respiratory symptoms. SARS-CoV-2 PCR was positive. Despite inpatient treatment for COVID-19 and a perianal abscess, the patient acutely decompensated, with worsening fever, tachycardia, fluid-refractory hypotension, elevation of liver enzymes, and transformation of the rash into purpura extending from the face to the trunk, upper and lower extremities, including the palmar and plantar surfaces of the hands and feet. Cytokine profile revealed rising levels of interleukin (IL)-6, IL-8, and TNF-alpha, higher than those described in either inflammatory bowel disease (IBD) or severe COVID-19 alone. The patient was treated with infliximab for TNF-alpha blockade to address both moderately to severely active Crohn's disease and multisystem inflammatory syndrome in children (MIS-C) temporally related to COVID-19. Within hours of infliximab treatment, fever, tachycardia and hypotension resolved. Cytokine profile improved with normalization of TNF-alpha, a decrease in IL-6, and IL-8 concentrations. This case supports a role for blockade of TNF-alpha in the treatment of COVID-19 inflammatory cascade. The role of anti-TNF agents in patients with MIS-C temporally related to COVID-19 requires further investigation."],"journal":"J Pediatr Gastroenterol Nutr","authors":["Dolinger, Michael T","Person, Hannibal","Smith, Rachel","Jarchin, Lauren","Pittman, Nanci","Dubinsky, Marla C","Lai, Joanne"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32452979","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1097/MPG.0000000000002809","locations":["Cytokine","Cytokine","Children"],"e_drugs":["Infliximab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667983494585778176,"score":190.6236},{"pmid":32171193,"title":"Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies.","text":["Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies.","Coronavirus-19 (COVI-19) involves humans as well as animals and may cause serious damage to the respiratory tract, including the lung: coronavirus disease (COVID-19). This pathogenic virus has been identified in swabs performed on the throat and nose of patients who suffer from or are suspected of the disease. When COVI-19 infect the upper and lower respiratory tract it can cause mild or highly acute respiratory syndrome with consequent release of pro-inflammatory cytokines, including interleukin (IL)-1beta and IL-6. The binding of COVI-19 to the Toll Like Receptor (TLR) causes the release of pro-IL-1beta which is cleaved by caspase-1, followed by inflammasome activation and production of active mature IL-1beta which is a mediator of lung inflammation, fever and fibrosis. Suppression of pro-inflammatory IL-1 family members and IL-6 have been shown to have a therapeutic effect in many inflammatory diseases, including viral infections. Cytokine IL-37 has the ability to suppress innate and acquired immune response and also has the capacity to inhibit inflammation by acting on IL-18Ralpha receptor. IL-37 performs its immunosuppressive activity by acting on mTOR and increasing the adenosine monophosphate (AMP) kinase. This cytokine inhibits class II histocompatibility complex (MHC) molecules and inflammation in inflammatory diseases by suppressing MyD88 and subsequently IL-1beta, IL-6, TNF and CCL2. The suppression of IL-1beta by IL-37 in inflammatory state induced by coronavirus-19 can have a new therapeutic effect previously unknown. Another inhibitory cytokine is IL-38, the newest cytokine of the IL-1 family members, produced by several immune cells including B cells and macrophages. IL-38 is also a suppressor cytokine which inhibits IL-1beta and other pro-inflammatory IL-family members. IL-38 is a potential therapeutic cytokine which inhibits inflammation in viral infections including that caused by coronavirus-19, providing a new relevant strategy.","J Biol Regul Homeost Agents","Conti, P","Ronconi, G","Caraffa, A","Gallenga, C","Ross, R","Frydas, I","Kritas, S","32171193"],"abstract":["Coronavirus-19 (COVI-19) involves humans as well as animals and may cause serious damage to the respiratory tract, including the lung: coronavirus disease (COVID-19). This pathogenic virus has been identified in swabs performed on the throat and nose of patients who suffer from or are suspected of the disease. When COVI-19 infect the upper and lower respiratory tract it can cause mild or highly acute respiratory syndrome with consequent release of pro-inflammatory cytokines, including interleukin (IL)-1beta and IL-6. The binding of COVI-19 to the Toll Like Receptor (TLR) causes the release of pro-IL-1beta which is cleaved by caspase-1, followed by inflammasome activation and production of active mature IL-1beta which is a mediator of lung inflammation, fever and fibrosis. Suppression of pro-inflammatory IL-1 family members and IL-6 have been shown to have a therapeutic effect in many inflammatory diseases, including viral infections. Cytokine IL-37 has the ability to suppress innate and acquired immune response and also has the capacity to inhibit inflammation by acting on IL-18Ralpha receptor. IL-37 performs its immunosuppressive activity by acting on mTOR and increasing the adenosine monophosphate (AMP) kinase. This cytokine inhibits class II histocompatibility complex (MHC) molecules and inflammation in inflammatory diseases by suppressing MyD88 and subsequently IL-1beta, IL-6, TNF and CCL2. The suppression of IL-1beta by IL-37 in inflammatory state induced by coronavirus-19 can have a new therapeutic effect previously unknown. Another inhibitory cytokine is IL-38, the newest cytokine of the IL-1 family members, produced by several immune cells including B cells and macrophages. IL-38 is also a suppressor cytokine which inhibits IL-1beta and other pro-inflammatory IL-family members. IL-38 is a potential therapeutic cytokine which inhibits inflammation in viral infections including that caused by coronavirus-19, providing a new relevant strategy."],"journal":"J Biol Regul Homeost Agents","authors":["Conti, P","Ronconi, G","Caraffa, A","Gallenga, C","Ross, R","Frydas, I","Kritas, S"],"date":"2020-03-16T11:00:00Z","year":2020,"_id":"32171193","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.23812/CONTI-E","keywords":["covid-19","il-1","il-6","pro-inflammatory cytokines","covi-19","sars-cov-2"],"locations":["swabs"],"e_drugs":["Adenosine"],"topics":["Treatment"],"weight":1,"_version_":1666138492607922178,"score":190.543},{"pmid":32472461,"title":"COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments.","text":["COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments.","Since December 2019, the pandemic caused by coronavirus disease 2019 (COVID-19) raises a real public health problem. COVID-19 appeared in Wuhan (Hubei province) in China. Drugs that have been used in rheumatology for decades seem to be effective in this infection and are for the most part being studied. The rational use of these anti-rheumatic drugs is based on the cytokinic storm (hyperproduction of IL1, IL6, TNF alpha) in the body by COVID-19 in its severe form. In this review, the authors make the difference between the infectious and auto-inflammatory part of COVID-19; the disease does not seem to be a risk factor for admission to the intensive care unit for patients suffering from inflammatory rheumatism; however, the poverty of studies on this subject should be noted. The authors also review anti-rheumatic drugs while studying COVID-19 treatment.","Clin Rheumatol","Ouedraogo, Dieu-Donne","Tiendrebeogo, Wendlassida Joelle Stephanie","Kabore, Fulgence","Ntsiba, Honore","32472461"],"abstract":["Since December 2019, the pandemic caused by coronavirus disease 2019 (COVID-19) raises a real public health problem. COVID-19 appeared in Wuhan (Hubei province) in China. Drugs that have been used in rheumatology for decades seem to be effective in this infection and are for the most part being studied. The rational use of these anti-rheumatic drugs is based on the cytokinic storm (hyperproduction of IL1, IL6, TNF alpha) in the body by COVID-19 in its severe form. In this review, the authors make the difference between the infectious and auto-inflammatory part of COVID-19; the disease does not seem to be a risk factor for admission to the intensive care unit for patients suffering from inflammatory rheumatism; however, the poverty of studies on this subject should be noted. The authors also review anti-rheumatic drugs while studying COVID-19 treatment."],"journal":"Clin Rheumatol","authors":["Ouedraogo, Dieu-Donne","Tiendrebeogo, Wendlassida Joelle Stephanie","Kabore, Fulgence","Ntsiba, Honore"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32472461","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s10067-020-05189-y","keywords":["covid-19","coronavirus","rheumatoid arthritis","treatment"],"locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1668255193344507904,"score":189.61778},{"pmid":32376392,"pmcid":"PMC7196557","title":"Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions.","text":["Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions.","The coronavirus disease-19 pandemic (COVID-19), which appeared in China in December 2019 and rapidly spread throughout the world, has forced clinicians and scientists to take up extraordinary challenges. This unprecedented situation led to the inception of numerous fundamental research protocols and many clinical trials. It quickly became apparent that although COVID-19, in the vast majority of cases, was a benign disease, it could also develop a severe form with sometimes fatal outcomes. Cytokines are central to the pathophysiology of COVID-19; while some of them are beneficial (type-I interferon, interleukin-7), others appear detrimental (interleukin-1beta, -6, and TNF-alpha) particularly in the context of the so-called cytokine storm. Yet another characteristic of the disease has emerged: concomitant immunodeficiency, notably involving impaired type-I interferon response, and lymphopenia. This review provides an overview of current knowledge on COVID-19 immunopathology. We discuss the defective type-I IFN response, the theoretical role of IL-7 to restore lymphocyte repertoire, as well as we mention the two patterns observed in severe COVID-19 (i.e. interleukin-1beta-driven macrophage activation syndrome vs. interleukin-6-driven immune dysregulation). Next, reviewing current evidence drawn from clinical trials, we examine a number of cytokine and anti-cytokine therapies, including interleukin-1, -6, and TNF inhibitors, as well as less targeted therapies, such as corticosteroids, chloroquine, or JAK inhibitors.","Autoimmun Rev","Jamilloux, Yvan","Henry, Thomas","Belot, Alexandre","Viel, Sebastien","Fauter, Maxime","El Jammal, Thomas","Walzer, Thierry","Francois, Bruno","Seve, Pascal","32376392"],"abstract":["The coronavirus disease-19 pandemic (COVID-19), which appeared in China in December 2019 and rapidly spread throughout the world, has forced clinicians and scientists to take up extraordinary challenges. This unprecedented situation led to the inception of numerous fundamental research protocols and many clinical trials. It quickly became apparent that although COVID-19, in the vast majority of cases, was a benign disease, it could also develop a severe form with sometimes fatal outcomes. Cytokines are central to the pathophysiology of COVID-19; while some of them are beneficial (type-I interferon, interleukin-7), others appear detrimental (interleukin-1beta, -6, and TNF-alpha) particularly in the context of the so-called cytokine storm. Yet another characteristic of the disease has emerged: concomitant immunodeficiency, notably involving impaired type-I interferon response, and lymphopenia. This review provides an overview of current knowledge on COVID-19 immunopathology. We discuss the defective type-I IFN response, the theoretical role of IL-7 to restore lymphocyte repertoire, as well as we mention the two patterns observed in severe COVID-19 (i.e. interleukin-1beta-driven macrophage activation syndrome vs. interleukin-6-driven immune dysregulation). Next, reviewing current evidence drawn from clinical trials, we examine a number of cytokine and anti-cytokine therapies, including interleukin-1, -6, and TNF inhibitors, as well as less targeted therapies, such as corticosteroids, chloroquine, or JAK inhibitors."],"journal":"Autoimmun Rev","authors":["Jamilloux, Yvan","Henry, Thomas","Belot, Alexandre","Viel, Sebastien","Fauter, Maxime","El Jammal, Thomas","Walzer, Thierry","Francois, Bruno","Seve, Pascal"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32376392","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.autrev.2020.102567","keywords":["anakinra","covid-19","cytokine storm","il-1","il-6","sars-cov2","tocilizumab","type-i interferon"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Chloroquine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666596532335411200,"score":187.59268}]}